Tribenzyltin carboxylates as anticancer drug candidates: Effect on the cytotoxicity, motility and invasiveness of breast cancer cell lines

被引:28
作者
Anasamy, Theebaa [1 ]
Thy, Chun Keng [2 ]
Lo, Kong Mun [2 ,3 ]
Chee, Chin Fei [2 ]
Yeap, Swee Keong [4 ]
Kamalidehghan, Behnam [5 ,6 ]
Chung, Lip Yong [1 ]
机构
[1] Univ Malaya, Dept Pharm, Fac Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur 50603, Malaysia
[3] Sunway Univ, Res Ctr Crystalline Mat, Petaling Jaya 47500, Selangor Darul, Malaysia
[4] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor Darul, Malaysia
[5] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran 1983963113, Iran
[6] NIGEB, Med Genet Dept, Tehran 1497716316, Iran
关键词
Organotin complexes; Tribenzyltin carboxylates; Anticancer; Antimotility; Apoptosis; Breast cancer; PROTEASOME INHIBITORS; IN-VITRO; PYRROLIDINE DITHIOCARBAMATE; CASPASE ACTIVATION; ANTITUMOR-ACTIVITY; APOPTOSIS; COMPLEXES; TUMOR; FLUORINE; ASSAY;
D O I
10.1016/j.ejmech.2016.09.061
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study seeks to investigate the relationship between the structural modification and bioactivity of a series of tribenzyltin complexes with different ligands and substitutions. Complexation with the N,N-diisopropylcarbamothioylsulfanylacetate or isonicotinate ligands enhanced the anticancer properties of tribenzyltin compounds via delayed cancer cell-cycle progression, caspase-dependent apoptosis induction, and significant reduction in cell motility, migration and invasion. Halogenation of the benzyl ring improved the anticancer effects of the tribenzyltin compounds with the N,N-diisopropylcarbamothioylsulfanylacetate ligand. These compounds also demonstrated far greater anticancer effects and selectivity than cisplatin and doxorubicin, which provides a rationale for their further development as anticancer agents. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:770 / 783
页数:14
相关论文
共 78 条
[21]   Morphological assessment of apoptosis [J].
Doonan, Francesca ;
Cotter, Thomas G. .
METHODS, 2008, 44 (03) :200-204
[22]   Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii [J].
Egorin, MJ ;
Sentz, DL ;
Rosen, DM ;
Ballesteros, MF ;
Kearns, CM ;
Callery, PS ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 39 (1-2) :51-60
[23]  
Esmat AY, 2005, CANCER BIOL THER, V4, P108
[24]   The Antiangiogenic and Antitumoral Activity of Titanocene Y* In Vivo [J].
Fichtner, Iduna ;
Behrens, Diana ;
Claffey, James ;
Deally, Anthony ;
Gleeson, Brendan ;
Patil, Siddappa ;
Weber, Holger ;
Tacke, Matthias .
LETTERS IN DRUG DESIGN & DISCOVERY, 2011, 8 (04) :302-307
[25]   Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy [J].
Fulda, S. ;
Debatin, K. -M .
ONCOGENE, 2006, 25 (34) :4798-4811
[26]   A Triphenyltin(IV) Nicotinate Derivative - Synthesis and Toxicity Towards Different Tumour and Normal Cell Lines [J].
Gomez-Ruiz, Santiago ;
Zizak, Zeljko ;
Kaluderovic, Goran N. .
LETTERS IN DRUG DESIGN & DISCOVERY, 2012, 9 (08) :737-741
[27]   Antiproliferative and anti-tumor activity of organotin compounds [J].
Hadjikakou, Sotiris K. ;
Hadjiliadis, Nick .
COORDINATION CHEMISTRY REVIEWS, 2009, 253 (1-2) :235-249
[28]   The many roles for fluorine in medicinal chemistry [J].
Hagmann, William K. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (15) :4359-4369
[29]   Choosing the right cell line for breast cancer research [J].
Holliday, Deborah L. ;
Speirs, Valerie .
BREAST CANCER RESEARCH, 2011, 13 (04)
[30]  
Hulkower Keren I, 2011, Pharmaceutics, V3, P107, DOI 10.3390/pharmaceutics3010107